In vivo treatment with these BMP6 signaling inhibitors in two mouse models of SS restored salivary gland secretion, decreased proinflammatory cells in the gland, decreased cytokines in the serum, and increased levels of TGF-β1, a cytokine often associated with regulatory T cell population. Here, TGFB1 is linked to synovial sarcoma.